JP2020105186A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020105186A5 JP2020105186A5 JP2020034938A JP2020034938A JP2020105186A5 JP 2020105186 A5 JP2020105186 A5 JP 2020105186A5 JP 2020034938 A JP2020034938 A JP 2020034938A JP 2020034938 A JP2020034938 A JP 2020034938A JP 2020105186 A5 JP2020105186 A5 JP 2020105186A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- neurodegenerative disorder
- disorder
- medicament according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims 5
- 229940121836 Phosphodiesterase 1 inhibitor Drugs 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 208000024412 Friedreich ataxia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 210000003050 axon Anatomy 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 150000003839 salts Chemical group 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799603P | 2013-03-15 | 2013-03-15 | |
| US61/799,603 | 2013-03-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018200930A Division JP2019031544A (ja) | 2013-03-15 | 2018-10-25 | 新規使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020105186A JP2020105186A (ja) | 2020-07-09 |
| JP2020105186A5 true JP2020105186A5 (enExample) | 2020-08-20 |
Family
ID=51538509
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503395A Withdrawn JP2016518343A (ja) | 2013-03-15 | 2014-03-17 | 新規使用 |
| JP2018200930A Withdrawn JP2019031544A (ja) | 2013-03-15 | 2018-10-25 | 新規使用 |
| JP2020034938A Pending JP2020105186A (ja) | 2013-03-15 | 2020-03-02 | 新規使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503395A Withdrawn JP2016518343A (ja) | 2013-03-15 | 2014-03-17 | 新規使用 |
| JP2018200930A Withdrawn JP2019031544A (ja) | 2013-03-15 | 2018-10-25 | 新規使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US9545406B2 (enExample) |
| EP (2) | EP2968338B1 (enExample) |
| JP (3) | JP2016518343A (enExample) |
| ES (2) | ES2717688T3 (enExample) |
| WO (1) | WO2014145617A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968338B1 (en) | 2013-03-15 | 2019-01-09 | Intra-Cellular Therapies, Inc. | Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| JP7134168B6 (ja) | 2016-09-12 | 2024-02-02 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| EP3746081A4 (en) * | 2018-01-31 | 2021-10-27 | Intra-Cellular Therapies, Inc. | Novel uses |
| US11980617B2 (en) | 2018-03-16 | 2024-05-14 | Intra-Cellular Therapies, Inc. | Methods of treating acute depression and/or acute anxiety |
| CN112189013A (zh) * | 2018-05-25 | 2021-01-05 | 细胞内治疗公司 | 有机化合物 |
| CA3102948A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2019241141A1 (en) * | 2018-06-11 | 2019-12-19 | The United States Government As Represented By The Department Of Veterans Affairs | Method for treating myocardial reperfusion injury using an inhibitor of the cyclic nucleotide phosphodiesterase pde1 |
| WO2020146384A1 (en) | 2019-01-07 | 2020-07-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US11628171B2 (en) * | 2019-03-13 | 2023-04-18 | Children's Medical Center Corporation | Method for treating brain or nerve injury |
| EP4413980A3 (en) * | 2019-09-03 | 2024-10-30 | Intra-Cellular Therapies, Inc. | Novel compounds |
| US20230355625A1 (en) * | 2019-11-27 | 2023-11-09 | Intra-Cellular Therapies, Inc. | Methods of treatment |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
| US20250144029A1 (en) * | 2022-01-27 | 2025-05-08 | Intra-Cellular Therapies, Inc. | Novel compositions |
| US20250195510A1 (en) | 2022-05-18 | 2025-06-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2025111568A1 (en) | 2023-11-22 | 2025-05-30 | Intra-Cellular Therapies, Inc. | Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6032638B2 (ja) | 1976-09-01 | 1985-07-29 | 武田薬品工業株式会社 | ３−アミノピラゾロ〔３，４−ｄ〕ピリミジン誘導体 |
| EP0077372A1 (de) | 1981-04-22 | 1983-04-27 | Byk Gulden Lomberg Chemische Fabrik GmbH | NEUE PYRAZOLO(3,4-d)PYRIMIDINE, VERFAHREN ZU DEREN HERSTELLUNG UND SIE ENTHALTENDE ARZNEIMITTEL |
| US4469868A (en) | 1982-05-24 | 1984-09-04 | Warner-Lambert Company | Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines |
| US4603203A (en) | 1983-12-14 | 1986-07-29 | Takeda Chemical Industries, Ltd. | 3-aminopyrazolo[3,4-d]pyrimidine derivatives and production thereof |
| US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
| KR920004437B1 (ko) | 1989-09-12 | 1992-06-05 | 삼성전자 주식회사 | 금전등록기의 거래선 관리방법 |
| NZ238609A (en) | 1990-06-21 | 1993-12-23 | Schering Corp | Polycyclic guanine derivatives; preparation, pharmaceutical compositions, |
| US5202328A (en) | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
| US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
| CA2156918A1 (en) | 1993-02-26 | 1994-09-01 | Deen Tulshian | 2-benzyl-polycyclic guanine derivatives and process for preparing them |
| GB9304919D0 (en) | 1993-03-10 | 1993-04-28 | Celltech Ltd | Chemical compounds |
| GB9315017D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| US5824683A (en) | 1995-11-28 | 1998-10-20 | Schering Corporation | 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones |
| GB9526245D0 (en) | 1995-12-21 | 1996-02-21 | Celltech Therapeutics Ltd | Chemical compounds |
| GB9622363D0 (en) | 1996-10-28 | 1997-01-08 | Celltech Therapeutics Ltd | Chemical compounds |
| JP2001507349A (ja) | 1996-12-23 | 2001-06-05 | セルテック セラピューティックス リミテッド | 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用 |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| US6013621A (en) | 1997-10-17 | 2000-01-11 | The Rockfeller University | Method of treating psychosis and/or hyperactivity |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| ES2356886T3 (es) | 1998-03-31 | 2011-04-14 | Kyowa Hakko Kirin Co., Ltd. | Compuestos heterocíclicos nitrogenados. |
| US6133273A (en) | 1998-05-08 | 2000-10-17 | American Home Products Corporation | Pyrazolopyrimidine-2,4-dione sulfonamides |
| US6459908B1 (en) | 1998-12-31 | 2002-10-01 | Qwest Communications International Inc. | Method and system for supporting wireless features in a Generic C wireline architecture |
| GB9907658D0 (en) | 1999-04-06 | 1999-05-26 | Zeneca Ltd | Chemical compounds |
| EP1206265B1 (en) | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| EP1194152A4 (en) | 1999-06-30 | 2002-11-06 | Merck & Co Inc | Links to SRC kinase inhibition |
| DE19931206A1 (de) | 1999-07-07 | 2001-01-11 | Stief Christian | Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung |
| ATE309241T1 (de) | 1999-09-10 | 2005-11-15 | Merck & Co Inc | Tyrosin kinase inhibitoren |
| AU7738100A (en) | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines |
| TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
| JP2003511452A (ja) | 1999-10-11 | 2003-03-25 | ファイザー・インク | ホスホジエステラーゼ阻害剤としての５−（２−置換−５−ヘテロシクリルスルホニルピリド−３−イル）−ジヒドロピラゾロ［４，３−ｄ］ピリミジン−７−オン |
| IL139073A0 (en) | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| AU2001255849B8 (en) | 2000-04-19 | 2006-04-27 | Lilly Icos, Llc. | PDE-V inhibitors for treatment of Parkinson's Disease |
| US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
| ES2241994T3 (es) | 2001-03-16 | 2005-11-01 | Pfizer Inc. | Compuestos pirazolo(4,3-d)pirimidinona como inhibidores de gmpc. |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| SE0102315D0 (sv) | 2001-06-28 | 2001-06-28 | Astrazeneca Ab | Compounds |
| CN1315835C (zh) | 2001-08-28 | 2007-05-16 | 先灵公司 | 多环鸟嘌呤磷酸二酯酶v抑制剂 |
| CA2459161A1 (en) | 2001-08-31 | 2003-03-13 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain |
| US6943171B2 (en) | 2001-11-09 | 2005-09-13 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase V inhibitors |
| HRP20040850A2 (en) | 2002-02-15 | 2005-08-31 | Synovo Gmbh | Conjugates of biologically active compounds, methods for their preparation and use formulation and pharmaceutical applications thereof |
| US20050153372A1 (en) | 2002-02-21 | 2005-07-14 | Paul Greengard | Compositions and method for regulation of calcium-dependent signaling in brain |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| US7666843B2 (en) * | 2002-09-27 | 2010-02-23 | Children's Medical Center Corporation | Methods and compositions for treatment of neurological disorder |
| AU2003276009A1 (en) * | 2002-10-01 | 2004-04-23 | Bayer Healthcare Ag | Regulation of human 3', 5' cyclic nucleotide phosphodiesterase pde1c |
| WO2004081563A2 (en) * | 2003-03-11 | 2004-09-23 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with phosphodiesterase 1a (pde1a) |
| EP1613747A1 (en) | 2003-03-31 | 2006-01-11 | Pfizer Products Inc. | Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof |
| BRPI0409229A (pt) | 2003-04-01 | 2006-03-28 | Applied Research Systems | inibidores das fosfodiesterases na infertilidade |
| CN1878773A (zh) | 2003-09-05 | 2006-12-13 | 神经能质公司 | 作为crf1受体配位体的杂芳基稠合的吡啶,吡嗪及嘧啶 |
| US20050287665A1 (en) * | 2004-06-23 | 2005-12-29 | Henrich Cheng | Method for inducing neural differentiation |
| CA2579569C (en) | 2004-09-08 | 2016-07-05 | Spinal Modulation Inc. | Neurostimulation methods and systems |
| CN101248050B (zh) | 2005-06-06 | 2013-07-17 | 武田药品工业株式会社 | 有机化合物 |
| EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
| KR20090042227A (ko) | 2006-06-06 | 2009-04-29 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| US20070286890A1 (en) | 2006-06-07 | 2007-12-13 | John Garnett Walt | Eyelash applicator and method |
| WO2008063505A1 (en) | 2006-11-13 | 2008-05-29 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
| AU2008331833A1 (en) | 2007-12-06 | 2009-06-11 | Intra-Cellular Therapies, Inc | Organic compounds |
| WO2009075784A1 (en) | 2007-12-06 | 2009-06-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20110098731A (ko) | 2008-12-06 | 2011-09-01 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| CN102232077A (zh) | 2008-12-06 | 2011-11-02 | 细胞内治疗公司 | 有机化合物 |
| EP2358204B1 (en) | 2008-12-06 | 2015-08-05 | Intra-Cellular Therapies, Inc. | 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors. |
| CN102223799A (zh) | 2008-12-06 | 2011-10-19 | 细胞内治疗公司 | 有机化合物 |
| WO2010065147A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2367429B1 (en) | 2008-12-06 | 2017-06-07 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP2400970A4 (en) * | 2009-02-25 | 2012-07-18 | Intra Cellular Therapies Inc | PDE-1-HEMMER FOR EYE DRESSING |
| US9468637B2 (en) | 2009-05-13 | 2016-10-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2013507360A (ja) | 2009-10-08 | 2013-03-04 | イントラ−セルラー・セラピーズ・インコーポレイテッド | ホスホジエステラーゼ１−標的トレーサーおよび方法 |
| MX339805B (es) | 2010-04-22 | 2016-06-10 | Intra Cellular Therapies Inc | Compuestos organicos. |
| WO2011153135A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP5879336B2 (ja) | 2010-05-31 | 2016-03-08 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| JP5911854B2 (ja) | 2010-05-31 | 2016-04-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| US10561656B2 (en) | 2011-06-10 | 2020-02-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP2014525927A (ja) | 2011-08-18 | 2014-10-02 | シャイアー アーゲー | 治療法に使用される５−ｈｔ４受容体アゴニスト及びｐｄｅ４阻害剤の組合せ |
| AR091507A1 (es) | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
| EP2968338B1 (en) | 2013-03-15 | 2019-01-09 | Intra-Cellular Therapies, Inc. | Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries |
| ES2836129T3 (es) | 2013-03-15 | 2021-06-24 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| JP7134168B6 (ja) | 2016-09-12 | 2024-02-02 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
-
2014
- 2014-03-17 EP EP14763482.8A patent/EP2968338B1/en active Active
- 2014-03-17 ES ES14763482T patent/ES2717688T3/es active Active
- 2014-03-17 EP EP18205841.2A patent/EP3479825B1/en active Active
- 2014-03-17 JP JP2016503395A patent/JP2016518343A/ja not_active Withdrawn
- 2014-03-17 WO PCT/US2014/030412 patent/WO2014145617A2/en not_active Ceased
- 2014-03-17 ES ES18205841T patent/ES2871327T3/es active Active
- 2014-03-17 US US14/777,448 patent/US9545406B2/en active Active
-
2017
- 2017-01-13 US US15/406,346 patent/US10183023B2/en active Active
-
2018
- 2018-10-25 JP JP2018200930A patent/JP2019031544A/ja not_active Withdrawn
- 2018-12-13 US US16/219,589 patent/US10682355B2/en active Active
-
2020
- 2020-03-02 JP JP2020034938A patent/JP2020105186A/ja active Pending
- 2020-05-20 US US16/879,676 patent/US11504372B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020105186A5 (enExample) | ||
| MX2022010044A (es) | Composicion farmaceutica que comprende microesferas de liberacion sostenida que incluyen analogo de glp-1 o sal farmaceuticamente aceptable del mismo. | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| RU2017112989A (ru) | Соединения и способы | |
| JP2016528301A5 (enExample) | ||
| BR112016025997A8 (pt) | compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica | |
| JP2019524822A5 (enExample) | ||
| JP2008534627A5 (enExample) | ||
| JP2014517050A5 (enExample) | ||
| HRP20191055T1 (hr) | Terapeutska sredstva za neurodegenerativne bolesti | |
| MX2022016276A (es) | Nuevos profarmacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson. | |
| CA2528160A1 (en) | Use of 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl) piperazine for neuronal regeneration and functional recovery | |
| JP2017511339A5 (enExample) | ||
| MX2019002444A (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
| BR112019024851A2 (pt) | agente para evitar ou tratar atrofia cerebral | |
| JP2018502163A5 (enExample) | ||
| BR112019024878A2 (pt) | Agente para prevenção ou tratamento de tauopatia | |
| CN101636159A (zh) | 用于预防和治疗阿尔茨海默型痴呆症的药物 | |
| EP3695847A4 (en) | FINE JET ESSENTIAL OIL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISEASES | |
| Kummer et al. | Dopamine dysregulation syndrome in Parkinson's disease: case report | |
| JP2019507786A5 (enExample) | ||
| JP2016528171A5 (enExample) | ||
| EP3911329A4 (en) | COMPOSITION FOR THE PREVENTION OR TREATMENT OF METABOLIC LIVER DISEASES | |
| EP3802568A4 (en) | PEPTIDE THERAPEUTICS USED TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES | |
| MX2020007941A (es) | Metodo para prevenir o tratar enfermedad de alzheimer. |